Cargando…

Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice

BACKGROUND: Type 1 diabetes (T1D) is associated with major chronic microvascular complications which contribute significantly to diabetes associated morbidity. The protein primarily responsible for glucose reabsorption in the kidney is sodium glucose co-transporter 2 (SGLT2). Presently, SGLT2 inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herat, Lakshini Y, Ward, Natalie C, Magno, Aaron L, Rakoczy, Elizabeth P, Kiuchi, Marcio G, Schlaich, Markus P, Matthews, Vance B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Basic Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336319/ https://www.ncbi.nlm.nih.gov/pubmed/32684737 http://dx.doi.org/10.3748/wjg.v26.i23.3225

Ejemplares similares

The Sympathetic Nervous System Regulates Sodium Glucose Co-Transporter 1 Expression in the Kidney
por: Matthews, Jennifer, et al.
Publicado: (2023)

Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy
por: Herat, Lakshini Y., et al.
Publicado: (2018)

The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α
por: Magno, Aaron L., et al.
Publicado: (2020)

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
por: Matthews, Jennifer, et al.
Publicado: (2022)

Current Knowledge of IL-6 Cytokine Family Members in Acute and Chronic Kidney Disease
por: Magno, Aaron L., et al.
Publicado: (2019)

The Effect of SGLT2 Inhibition on Diabetic Kidney Disease in a Model of Diabetic Retinopathy
por: Matthews, Jennifer Rose, et al.
Publicado: (2022)

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
por: Matthews, Jennifer, et al.
Publicado: (2023)

The Schlager mouse as a model of altered retinal phenotype
por: Herat, Lakshini Y., et al.
Publicado: (2019)

SGLT2 Inhibitor-Induced Sympathoexcitation in White Adipose Tissue: A Novel Mechanism for Beiging
por: Matthews, Jennifer R., et al.
Publicado: (2020)

Sympathetic stimulation with norepinephrine may come at a cost
por: Herat, Lakshini Y., et al.
Publicado: (2019)

SGLT2 Inhibitor–Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection
por: Herat, Lakshini Y., et al.
Publicado: (2020)

Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes
por: Matthews, Jennifer, et al.
Publicado: (2021)

SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes
por: Herat, Lakshini Yasaswi, et al.
Publicado: (2023)

Combined renal and common hepatic artery denervation as a novel approach to reduce cardiometabolic risk: technical approach, feasibility and safety in a pre-clinical model
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2021)

Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition
por: Herat, Lakshini Y., et al.
Publicado: (2022)

The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice
por: Herat, Lakshini, et al.
Publicado: (2017)

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—A Condition Associated with Heightened Sympathetic Activation
por: Carnagarin, Revathy, et al.
Publicado: (2021)

TNFSF14-Derived Molecules as a Novel Treatment for Obesity and Type 2 Diabetes
por: Agostino, Mark, et al.
Publicado: (2021)

Supine blood pressure—A clinically relevant determinant of vascular target organ damage in hypertensive patients
por: Nolde, Janis M., et al.
Publicado: (2020)

The molecular basis for the neutral effect of renal denervation in patients with chronic heart failure not responding to cardiac resynchronisation therapy – a perspective
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2019)

Multi-organ denervation: a novel approach to combat cardiometabolic disease
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2023)

Microvascular changes at different stages of chronic kidney disease
por: Kannenkeril, Dennis, et al.
Publicado: (2020)

Sympathetic Nervous System Activation and Its Modulation: Role in Atrial Fibrillation
por: Carnagarin, Revathy, et al.
Publicado: (2019)

Retinal capillary rarefaction is associated with arterial and kidney damage in hypertension
por: Frost, Shaun, et al.
Publicado: (2021)

Renal denervation as a synergistic tool for the treatment of polymorphic ventricular ectopic beats: A case report
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2020)

Relevance of Targeting the Distal Renal Artery and Branches with Radiofrequency Renal Denervation Approaches—A Secondary Analysis from a Hypertensive CKD Patient Cohort
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2019)

Sympathetic Activation in Hypertensive Chronic Kidney Disease – A Stimulus for Cardiac Arrhythmias and Sudden Cardiac Death?
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2020)

Glucose transporter expression in the human colon
por: Merigo, Flavia, et al.
Publicado: (2018)

A cautionary note for researchers treating mice with the neurotransmitter norepinephrine
por: Matthews, Vance B., et al.
Publicado: (2018)

Type and capacity of glucose transport influences succinate yield in two-stage cultivations
por: Kyselova, L., et al.
Publicado: (2018)

ADAM19: A Novel Target for Metabolic Syndrome in Humans and Mice
por: Weerasekera, Lakshini, et al.
Publicado: (2017)

2394 Sodium-glucose transporter 2 is a novel diagnostic and therapeutic target for early-stage lung adenocarcinoma
por: Scafoglio, Claudio, et al.
Publicado: (2018)

Mibefradil reduces blood glucose concentration in db/db mice
por: Lu, Yujie, et al.
Publicado: (2014)

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
por: Armour, Sarah L., et al.
Publicado: (2022)

SMIT (Sodium-Myo-Inositol Transporter) 1 Regulates Arterial Contractility Through the Modulation of Vascular Kv7 Channels
por: Barrese, Vincenzo, et al.
Publicado: (2020)

New Approaches in the Management of Sudden Cardiac Death in Patients with Heart Failure—Targeting the Sympathetic Nervous System
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2019)

Engineering of Yarrowia lipolytica transporters for high-efficient production of biobased succinic acid from glucose
por: Jiang, Zhennan, et al.
Publicado: (2021)

Vanadium-dependent activation of glucose transport in adipocytes by catecholamines is not mediated via adrenoceptor stimulation or monoamine oxidase activity
por: Fontaine, Jessica, et al.
Publicado: (2020)

High doses of catecholamines activate glucose transport in human adipocytes independently from adrenoceptor stimulation or vanadium addition
por: Carpéné, Christian, et al.
Publicado: (2022)

Role of sodium‐glucose transporters in glucose uptake of the intestine and kidney
por: Harada, Norio, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_klfbo1dqsv8eagnbs364h4v9ak